SIS
LCTX icon

Strategic Investment Solutions’s Lineage Cell Therapeutics LCTX Stock Holding History

Strategic Investment Solutions’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44
Closed -$73 – 685
2025
Q4 		$73 Hold
44
– – ﹤0.01% 611
2025
Q3 		$74 Hold
44
– – ﹤0.01% 590
2025
Q2 		$40 Hold
44
– – ﹤0.01% 591
2025
Q1 		$20 Hold
44
– – ﹤0.01% 627
2024
Q4 		$48 Hold
44
– – ﹤0.01% 631
2024
Q3 		$40 Hold
44
– – ﹤0.01% 634
2024
Q2 		$45 Buy
+44
New +$49 ﹤0.01% 598
2023
Q4 		$48 Buy
+44
New +$48 ﹤0.01% 1107
2023
Q2 		– Sell
-44
Closed -$66 – 931
2023
Q1 		$66 Buy
+44
New +$61 ﹤0.01% 1000

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Strategic Investment Solutions's LCTX Position: Q1 2026 in Review

Strategic Investment Solutions sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 44 shares — an estimated $73 sold.

Strategic Investment Solutions first reported a position in LCTX in Q1 2023 and held it in 9 quarters. The position peaked at $74 in Q3 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Strategic Investment Solutions reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Strategic Investment Solutions sold 44 Lineage Cell Therapeutics shares in Q1 2026, an estimated $73.
  • Strategic Investment Solutions first reported a position in Lineage Cell Therapeutics in Q1 2023 and held it in 9 quarters.
  • Strategic Investment Solutions's Lineage Cell Therapeutics position peaked at $74 in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Strategic Investment Solutions's 13F filing for Q1 2026, filed 1 May 2026.